I am a
Home I AM A Search Login

Papers of the Week

Papers: 6 Apr 2019 - 12 Apr 2019

Pharmacology/Drug Development


2019 Jun

Curr Opin Neurol



How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient’s perspective.


Torres-Ferrus M, Alpuente A, Pozo-Rosich P
Curr Opin Neurol. 2019 Jun; 32(3):395-404.
PMID: 30950844.


Migraine is a prevalent and extremely disabling brain disorder, with an impact on the individual, family, workplace and society. This review focuses on describing Calcitonin Gene Related Peptide Monoclonal Antibodies (CGRP-mABs) efficacy on improving the quality of life (QoL) and decreasing the disability and impact of migraine measured with patient related outcomes (PROs), on patients who participated in clinical trials with erenumab, fremanezumab, galcanezumab and eptinezumab. The goal is to better reflect the effect of these preventive migraine treatments in the daily life of our patients.